Medical Access and Reimbursement in Comoros

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. The Union of the Comoros is party to international drug control treaties that require control of psychotropic substances, which underpin national prohibition of non‑medical uses. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of an established national medical program, licensing, or reimbursement for MDMA‑assisted therapy in the Comoros; access would be limited to approved international clinical trials if any occur. #

Currently classified under controlled‑substance frameworks with no publicly documented national approval, reimbursement, or registered product authorization for esketamine (Spravato®) in the Comoros. There is no indication of a national regulatory approval or public reimbursement pathway for esketamine; any access would therefore be limited to participation in an approved clinical trial or import under special authorization if permitted. The broader international treaty obligations inform national control measures. # #

Ketamine is listed on the World Health Organization Model List of Essential Medicines for use as an injectable general anaesthetic and is widely used internationally in low‑ and middle‑income health systems for surgical and emergency anaesthesia; this WHO listing supports routine medical availability of ketamine in many countries, including resource‑limited settings. #

In the Comoros there is no public information indicating a national, publicly funded reimbursement program for ketamine when used for investigational or off‑label psychiatric indications (for example, treatment‑resistant depression). Available evidence and standard practice in similar health systems indicate that ketamine’s primary lawful medical use in the country would be as an anaesthetic or procedural sedative provided within hospitals or clinical facilities; procurement and use for these indications are typically handled through hospital budgets, private providers, or donor/NGO supplies rather than a dedicated reimbursed mental‑health program. There is no publicly available regulatory approval notice, national formulary listing, or Ministry of Health guidance showing ketamine is reimbursed for psychiatric indications in the Comoros. #

Operationally this means: ketamine is likely available and lawfully used in medical/surgical settings (consistent with WHO essential‑medicines guidance), but there is no structured national reimbursement pathway or formal program in Comoros for ketamine‑based psychiatric treatment; off‑label psychiatric uses would therefore be ad hoc, clinician‑led, and not publicly reimbursed. (If you require confirmation of hospital‑level availability or procurement mechanisms in a specific Comorian hospital or region, I can look up national procurement lists or contactable ministry documents.) #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. There is no public record of national medical authorization or reimbursement for DMT in the Comoros. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. No national authorization or reimbursement pathway has been identified for 5‑MeO‑DMT in Comoros. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of regulated medical or reimbursed ibogaine treatment availability in the Comoros. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Traditional plant‑based preparations containing DMT (commonly referred to as ayahuasca) would be controlled under the same national controls applicable to DMT and similar psychotropics. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of a national medical or reimbursed program for mescaline in the Comoros. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Novel phenethylamines (the 2C family) are controlled under international and national psychotropic substance controls and are not authorized or reimbursed for medical treatment in the Comoros. #